Generic drug manufacturer Ranbaxy Laboratories Ltd. will pay $500 million to resolve civil and criminal cases over the introduction of substandard generic drugs into interstate commerce, the Department of Justice announced May 13 (United States v. Ranbaxy USA Inc.).
The government said the settlement with India-based Ranbaxy is the largest drug safety settlement to date with a generic drug firm. Under the settlement, Ranbaxy will pay the government $150 million in the form of a $130 million criminal fine and a $20 million forfeiture. The company also will pay $350 million to settle to settle civil claims under ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.